诺和诺德公司的历史可追溯到 80 多年前一对丹麦夫妇 August Krogh 及妻子 Marie Krogh 的一次美国之旅。是这次旅行，使他们了解到加拿大科学家用牛胰腺提取出的胰岛素为患者治疗糖尿病的信息，并获得了在丹麦生产胰岛素的特许，也促成了“诺德”和“诺和”两家胰岛素制造企业的诞生。在此后 65 年并驾齐驱、竞争相长的发展过程中，“诺德”和“诺和”公司一直运用国际最前沿的生物研究方法，不断推陈出新，双双成为这一领域的先驱。 1989 年，“诺德”和“诺和”两家公司决定合并重组，成立了诺和诺德公司，同心协力开发糖尿病治疗新产品、征战国际市场。 2000 年，为了扩大公司在相应专业领域的领先优势，诺和诺德决定再次进行结构调整。形成了今天的诺和诺德公司。
诺和诺德公司是糖尿病治疗领域的先导
诺和诺德公司始终是世界胰岛素治疗重大发明的先锋，迄今为止，世界上主要胰岛素制剂和先进的胰岛素给药系统均出自诺和诺德公司。可以说，诺和诺德公司的研发史同时也是人类利用胰岛素治疗糖尿病的历史。
1923 诺德胰岛素实验室创立
1925 诺和 Terapeutisk 实验室创立
1932 诺德胰岛素实验室创立 Steno 纪念医院
1938 诺和公司成立
HvidØre
糖尿病疗养院
1951 诺和基金会成立，旨在支持科学、社会和人道主义事业，并为公司提供最大限度的保护
1974 诺和公司 B 股在哥本哈根证券交易所挂牌交易
1981 诺和公司成为在纽约证券交易所挂牌交易的第一家北欧公司
1989 诺和公司与诺德公司合并组成世界领先的胰岛素制造商 - 诺和诺德
1992 Steno 纪念医院与 HvidØre 医院合并成立 Steno 糖尿病中心
1994 诺和诺德公司是丹麦第一家发布环境报告的企业，也是世界上最早出版环境报告的企业之一
1999 诺和诺德公司发布其第一份社会报告
2000 诺和诺德公司分成隶属诺和集团的三个独立运营公司：诺和诺德公司、诺维信公司及诺和公司
2001 诺和诺德公司收购巴西制药公司 Biobrás
2001 诺和诺德公司创立世界糖尿病基金会，旨在提高发展中国家的糖尿病防治水平
The Novo Nordisk History
Novo Nordisk's history spans more than 80 years. The story begins in 1922 when a Danish couple, August and Marie Krogh, traveled to America . It's the journey that help them get the information that two Canadian researchers were treating people with diabetes with an insulin extracted from bovine pancreases and be granted permission to produce the vital insulin in Denmark,as well as bring about the birth of Novo Nordisk. Since then ,the company continues to adopt advanced biotechnology to improve the research and means of production for insulin and therefore becomes a world leader in diabetes care. In 1989 Novo and Nordisk decided to merge into Novo Nordisk and started to concentrate their combined forces on developing new products for treating diabetes and on conquering world markets. In 2000, Novo Nordisk decided to make another organization adjustment in order to enable the core businesses to increase their operational freedom and focus on what they do best .This adjustment brought the establishment of new Novo Nordisk.
Novo Nordisk – A World Leader in Diabetes Care
Novo Nordisk has been a pioneer in the field of insulin research and development. So far, most of the main insulin preparations and advanced insulin delivery systems are first introduced by Novo Nordisk. In fact , the R&D history of Novo Nordisk is also the one of people treating diabetes with insulin.
| 1923 |
Nordisk Insulinlaboratorium founded. |
| 1925 |
Novo Terapeutisk Laboratorium founded. |
| 1932 |
Nordisk Insulinlaboratorium founds the Steno Memorial Hospital . |
| 1938 |
Novo founds HvidØre Diabetes Sanatorium. |
| 1951 |
The Novo Foundation is set up with object of supporting scientific, social and humanitarian causes, and to provide the best possible protection for the company. |
| 1974 |
Novo's B shares are quoted on the Copenhagen Stock Exchange. |
| 1981 |
Novo becomes the first company in Scandinavia to be quoted on the New York Stock Exchange. |
| 1989 |
Novo Industri A/S and Nordisk Gentofte A/S merge to become the world's leading producer of insulin. |
| 1992 |
The Steno Memorial Hospital and HvidØre Hospital merge to form the Steno Diabetes Center . |
| 1994 |
Novo Nordisk is the first company in Denmark – and one of the first in the world – to publish an environmental report. |
| 1999 |
Novo Nordisk publishes its first social report. |
| 2000 |
Novo Nordisk is split into three separate companies operating under the umbrella of the Novo Group: Novo Nordisk A/S, Novozymes A/S and Novo A/S. |
| 2001 |
Novo Nordisk acquires the controlling interest in the Brazilian pharmaceutical company Biobrás. |
| 2001 |
Novo Nordisk establishes the World Diabetes Foundation with the purpose of improving diabetes care in developing countries. |
|
